These trials revealed heightened risks, including increased Candida albicans infections in IBD patients’ intestinal mucosa and severe adverse events leading to the premature cessation of an anti-IL-17 treatment trial for CD (60, 61). The gene discussed is IL17A; the disease is inflammatory bowel disease.